ANDREW SHER to Immunotherapy, Adoptive
This is a "connection" page, showing publications ANDREW SHER has written about Immunotherapy, Adoptive.
Connection Strength
0.031
-
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 06; 29(6):1379-1388.
Score: 0.031